VG Life Sciences Inc.
VGLS
$0.00
$0.000.00%
| Weiss Ratings | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 26.91 | |||
| Price History | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -100.00% | |||
| 30-Day Total Return | -100.00% | |||
| 60-Day Total Return | -100.00% | |||
| 90-Day Total Return | -100.00% | |||
| Year to Date Total Return | -100.00% | |||
| 1-Year Total Return | -100.00% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -100.00% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -50.00% | |||
| 52-Week Low % Change | 4,900.00% | |||
| Price | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Apr 04, 2024 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.05M | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -- | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | -- | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 805 879 9000 | |||
| Address | 121 Gray Avenue Santa Barbara, CA 93101 | |||
| Website | www.vglifesciences.com | |||
| Country | United States | |||
| Year Founded | 1995 | |||
| Profitability | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -151.18% | |||
| Return on Equity | -- | |||
| Income Statement | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -2.73M | |||
| Net Income (TTM) | -4.30M | |||
| Net Income Avl. to Common (TTM) | -4.30M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 4.65% | |||
| EPS Diluted (TTM) | -0.07 | |||
| EPS Diluted Growth (Q YOY) | 67.57% | |||
| Balance Sheet | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 22.90K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 40.30K | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | -4.34M | |||
| Current Ratio (Q) | 0.007 | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | 5.46M | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | -4.98M | |||
| Cash Flow | VGLS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 827.40K | |||
| Net Change in Cash (TTM) | -30.90K | |||
| Levered Free Cash Flow (TTM) | -1.53M | |||
| Cash from Operations (TTM) | -858.30K | |||
